PAX8 Reliably Distinguishes Ovarian Serous Tumors From Malignant Mesothelioma

被引:180
作者
Laury, Anna R.
Hornick, Jason L. [3 ]
Perets, Ruth [2 ]
Krane, Jeffrey F. [3 ]
Corson, Joseph [3 ]
Drapkin, Ronny [2 ,3 ]
Hirsch, Michelle S. [1 ,3 ]
机构
[1] Brigham & Womens Hosp, Dept Pathol, Womens & Perinatal Pathol Div, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Dept Med Oncol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
关键词
PAX8; h-caldesmon; serous; borderline; mesothelioma; peritoneal; HUMAN PROTEIN ATLAS; PAIRED BOX GENE; H-CALDESMON; PERITONEAL MESOTHELIOMA; PLEURAL MESOTHELIOMA; BORDERLINE TUMORS; THYROID-TUMORS; LOW-GRADE; EXPRESSION; CANCER;
D O I
10.1097/PAS.0b013e3181da7687
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Ovarian serous neoplasms can have morphologic overlap with malignant mesothelioma. The distinction is clinically important, yet most studies have failed to identify immunostains that reliably distinguish these 2 tumor types. Recently, transcription factor PAX8 was shown to be a sensitive and relatively specific marker for Mullerian tumors. In addition, some studies suggest that h-caldesmon is sensitive and specific for mesothelioma when compared with serous ovarian tumors. The goal of this study was to evaluate whether PAX8 and h-caldesmon expression can successfully distinguish mesothelioma from serous ovarian tumors. Immunohistochemistry was carried out using PAX8 and h-caldesmon antibodies on archival tissue from 254 ovarian serous tumors and 50 mesothelial tumors. Nuclear and cytoplasmic immunoreactivity were considered positive for PAX8 and h-caldesmon, respectively. PAX8 staining was present in 99% of high-grade serous ovarian carcinomas and all (100%) low-grade ovarian carcinomas and serous borderline tumors; however, only 74% of these cases (188/254) were diffusely positive in more than 50% of tumors cells, and intensity ranged from strong to weak. None of the pleural malignant mesotheliomas were reactive with PAX8. However, 2/23 (9%) peritoneal malignant mesotheliomas showed focal and/or weak staining for PAX8; the remaining cases were negative. Two well-differentiated papillary mesotheliomas and 1 multicystic mesothelioma each showed some staining for PAX8. h-caldesmon was negative in all serous neoplasms and all mesothelial neoplasms, except 1 pleural malignant mesothelioma which showed patchy immunoreactivity. Strong PAX8 staining is highly specific (P < 0.00001) for ovarian serous tumors when compared with malignant mesotheliomas of the peritoneum and pleura. The presence of weak staining for PAX8 in the 3 "noninvasive" mesotheliomas questions the use for PAX8 in this differential diagnosis. On the basis of this study, h-caldesmon is not a useful marker for mesothelioma.
引用
收藏
页码:627 / 635
页数:9
相关论文
共 55 条
[1]  
[Anonymous], TUMORS SEROSAL MEMBR
[2]   Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors - Diagnostic implications [J].
Bakshi, Nasir ;
Kunju, Lakshmi P. ;
Giordano, Thomas ;
Shah, Rajal B. .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2007, 15 (03) :310-315
[3]   Immunohistochemical analysis of peritoneal mesothelioma and primary and secondary serous carcinoma of the peritoneum - Ant bodies to estrogen and progesterone receptors are useful [J].
Barnetson, RJ ;
Burnett, RA ;
Downie, I ;
Harper, CM ;
Roberts, F .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2006, 125 (01) :67-76
[4]   A Genecentric Human Protein Atlas for Expression Profiles Based on Antibodies [J].
Berglund, Lisa ;
Bjoerling, Erik ;
Oksvold, Per ;
Fagerberg, Linn ;
Asplund, Anna ;
Szigyarto, Cristina Al-Khalili ;
Persson, Anja ;
Ottosson, Jenny ;
Wernerus, Henrik ;
Nilsson, Peter ;
Lundberg, Emma ;
Sivertsson, Asa ;
Navani, Sanjay ;
Wester, Kenneth ;
Kampf, Caroline ;
Hober, Sophia ;
Ponten, Fredrik ;
Uhlen, Mathias .
MOLECULAR & CELLULAR PROTEOMICS, 2008, 7 (10) :2019-2027
[5]   Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. [J].
Bonome, T ;
Lee, JY ;
Park, DC ;
Radonovich, M ;
Pise-Masison, C ;
Brady, J ;
Gardner, GJ ;
Hao, K ;
Wong, WH ;
Barrett, JC ;
Lu, KH ;
Sood, AK ;
Gershenson, DM ;
Mok, SC ;
Birrer, MJ .
CANCER RESEARCH, 2005, 65 (22) :10602-10612
[6]   Emerging roles for PAX8 in ovarian cancer and endosalpingeal development [J].
Bowen, Nathan J. ;
Logani, Sanjay ;
Dickerson, Erin B. ;
Kapa, Laura B. ;
Akhtar, Mariam ;
Benigno, Benedict B. ;
McDonald, John F. .
GYNECOLOGIC ONCOLOGY, 2007, 104 (02) :331-337
[7]   Pathology and classification of ovarian tumors [J].
Chen, VW ;
Ruiz, B ;
Killeen, JL ;
Coté, TR ;
Wu, XC ;
Correa, CN .
CANCER, 2003, 97 (10) :2631-+
[8]   Getting your Pax straight: Pax proteins in development and disease [J].
Chi, N ;
Epstein, JA .
TRENDS IN GENETICS, 2002, 18 (01) :41-47
[9]   Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma [J].
Chu, AY ;
Litzky, LA ;
Pasha, TL ;
Acs, G ;
Zhang, PJ .
MODERN PATHOLOGY, 2005, 18 (01) :105-110
[10]   h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: A useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary [J].
Comin, Camilla E. ;
Saieva, Calogero ;
Messerini, Luca .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2007, 31 (08) :1139-1148